Trial Profile
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Brentuximab vedotin
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-204
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 17 Jun 2022 Results from four KEYNOTE-013 (NCT01953692, n=20), KEYNOTE-087 (NCT02453594, n=31), KEYNOTE-170 (NCT02576990, n=5), and KEYNOTE-204 (NCT02684292) trials presented at the 27th Congress of the European Haematology Association
- 17 Mar 2021 According to a Merck and Co media release, the European Commission (EC) approval is based on results from the pivotal Phase 3 KEYNOTE-204 trial and supportive data from an updated analysis of the KEYNOTE-087 trial.
- 17 Mar 2021 According to a Merck and Co media release, the European Commission (EC) has approved an expanded label for KEYTRUDA (pembrolizumab), as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.